If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-24. Numbers and descriptions here follow the published literature rather than marketing material.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | 31 amino acids |
| Backbone modification | Aib at position 8 | Blocks DPP-4 cleavage |
| Fatty acid chain | C18 diacid | Supports albumin binding |
| Native half-life | 1 to 2 minutes | Endogenous GLP-1 |
| Analog half-life | Approximately one week | Extended by albumin binding |
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
=== Terminal === Memphis International Airport has one terminal with a Y-shaped concourse. There are 23 gates on the central stem and southeastern leg of the concourse. All international flights that are not precleared at the departure airport are processed on the southwestern leg. The terminal was built in 1963, and by the 1970s it had three concourses. The west concourse was labeled A, the middle one B, and the east one C. As of 2013, the year that the Delta hub closed, the terminal had over 70 gates. When the refurbished Concourse B began operations in 2022, all flights were consolidated there and the other two concourses closed. The demolition of Concourse A started in 2025.
==== Antigenic stability and cross-reactive antibodies ==== All viruses in the family Paramyxoviridae are antigenically stable; therefore the family representatives that are close relatives and belong to the same genus, most likely, share common antigenic determinants. Thus, porcine parainfluenza 1, which has high sequence homology with SeV and also belongs to the same genus Respirovirus as SeV, probably, has cross-reactive antibodies with SeV. Perhaps the porcine parainfluenza 1 was responsible for pigs disease in Japan in 1953–1956. However, the antigenic cross-reactivity among these two representatives within the genus Respirovirus may explain why SeV antibodies were found in sick pigs, and why it was thought that SeV was the etiological causative agent of pigs disease. Human parainfluenza virus type 1 also shares common antigenic determinants with SeV and triggers the generation of cross-reactive neutralizing antibodies. This fact can explain wide spread detection of SeV antibodies in humans in the 1950s–1960s. Recently published study also showed this wide spread detection. The study that was published in 2011 demonstrated that SeV neutralizing antibodies (which were formed due to human parainfluenza virus type 1 past infection) can be detected in 92.5% of human subjects worldwide with a median EC50 titer of 60.6 and values ranging from 5.9 to 11,324. Low anti-SeV antibodies background does not block the ability of SeV-base vaccine to promote antigen-specific T cell immunity.
=== Genetics === The American cockroach genome is the second-largest insect genome on record, after Locusta migratoria. Around 60% of its genome is composed of repeat elements. Around 90% of the genome can be found in other members of Blattodea. The genome codes for a large number of chemoreceptor families, including 522 taste receptors and 154 olfactory receptors. The 522 taste receptors comprise the largest number found among insects for which genomes have been sequenced. About 329 of the taste receptors are involved in bitter taste perception. These traits, along with enlarged groups of genes relating to detoxification, the immune system, and growth and reproduction, are believed to be part of the reasons behind the cockroach's ability to adapt to human living spaces.
=== Restrictions to trading with China === US politicians and European industry players have invoked the looming AI Cold War as a reason to ban procurement by public authorities in Europe of Huawei 5G technology due to concerns over the Chinese state-sponsored surveillance industry. In 2019, the Trump administration successfully lobbied the Dutch government into stopping the Netherlands-based company ASML from exporting equipment to China. ASML manufactures a machine called an extreme ultraviolet lithography system used by semiconductor producers, including TSMC and Intel to produce state-of the-art microchips. The Biden administration adopted the same course of action as the Trump administration and requested the Netherlands to restrict sales by ASML to China, invoking national-security concerns. The trade restrictions imposed by the Trump administration affected semiconductors imports from China to the US and raised concerns by the US industry that supply chains will be disrupted in case of an AI Cold War. This prompted US technology companies to develop mitigation strategies including hoarding semiconductors and trying to set up local semiconductor production facilities, with the support of government subsidies.
Sources: en.wikipedia.org
== Good clinical data management practice == Good clinical data management practice (GCDMP) is the current industry standards for clinical data management that consist of best business practice and acceptable regulatory standards. In all phases of clinical trials, clinical and laboratory information must be collected and converted to digital form for analysis and reporting purposes. The U.S. Food and Drug Administration and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use have provided specific regulations and guidelines surrounding this component of the drug and device development process. The effective, efficient and regulatory-compliant management of clinical trial data is an essential component of drug and device development. The Society for Clinical Data Management (SCDM) has created the Good Clinical Data Management Practices (GCDMP©) standard, a comprehensive document that provides guidance on accepted practices of clinical data management (CDM) that are not totally covered by current guidelines and regulations. This document is updated by Subject Matter Experts on a continuous basis.
ILP solvers, such as CPLEX, can compute the exact optimal solution for large instances of protein design problems. These solvers use a linear programming relaxation of the problem, where qi and qij are allowed to take continuous values, in combination with a branch and cut algorithm to search only a small portion of the conformation space for the optimal solution. ILP solvers have been shown to solve many instances of the side-chain placement problem.
Nonetheless, it retains clinically meaningful opioid activity, contributing to its analgesic effects. Commercial formulations contain only the (R,R)-stereoisomer. Drugs with high MOR affinity, such as tapentadol, carry an abuse potential comparable to other strong opioids like morphine, oxycodone, and hydromorphone.
Transporter competition: Many GalNAc-conjugated siRNA drugs (e.g., inclisiran, givosiran, lumasiran) are taken up by hepatocytes via the asialoglycoprotein receptor (ASGPR). Co-administration of agents that saturate or alter this receptor pathway may affect hepatic delivery of the siRNA payload. Carrier protein binding: Some oligonucleotide drugs bind serum albumin or lipoproteins. Competition with highly protein-bound small molecules could alter free-drug concentrations. Indirect CYP modulation: siRNA drugs that silence transcription factors controlling CYP gene expression (e.g., silencing of PCSK9 influences LXR/SREBP pathways) may indirectly alter CYP expression in co-treated patients. On-target miRNA network perturbation: Because endogenous microRNA (miRNA) regulates the expression of drug-metabolizing enzymes and transporters, therapeutic oligonucleotides that modulate miRNA activity can produce secondary DDIs via altered enzyme expression rather than direct enzyme binding.
Mōri Motonari issued each soldier a bag of rice, fried rice, and mochi, the latter of which was chosen due to its portability, long shelf life, ability to provide high energy in small amounts, and Motonari's personal preference for it. Uesugi Kenshin would prepare massive feasts for his army before battles, known as kachidoki-meshi ("victory cry meals"), featuring delicacies such as "a mountain of rice ... black-boiled abalone, vinegar-washed fish and jellyfish sashimi, soups with seasonal vegetables and dried fish, walnut-roasted duck, simmered sand borer, and more", though Kenshin himself was noted to eat very little. During battles, Kenshin assembled supply convoys called konidatai staffed by peasants, who would deliver supplies and rations to troops. Toyotomi Hideyoshi is said to have regularly distributed food rations out to his officers and soldiers, and kept them well-fed. In one instance, while traveling from Ogaki to Nagahama (a 52 kilometer distance) in 1583, Hideyoshi sent scouts ahead to each village to ask that they prepare rice for Hideyoshi's army; the villages set out rice balls for the soldiers, allowing them to remain fed for the entire trip. In general, Japanese soldiers would bring uchigaibukuro, pouches used to store rice and medicine, into battle with them. They would also eat miso, dried taro stalk, and okayu as part of a soup prepared in a soldier's jingasa.
Sources: en.wikipedia.org
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.
A fatty acid side chain attaches the peptide to serum albumin, which shields it from kidney filtration and protease activity. This interaction is the main reason its circulation time is extended.
No. The native hormone is GLP-1, and semaglutide is an engineered variant with three deliberate structural alterations. It does not appear in unmodified biological sources.
冻融过程中冰晶形成与局部浓度升高会促使肽链发生界面吸附和聚集。聚集不仅降低有效含量，还会改变可见异物与不溶性微粒的计数结果。将溶液分装为单次使用的小体积等份可减少循环次数。